Related references
Note: Only part of the references are listed.Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily
C. Sillaber et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2009)
The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro
Stephen Blake et al.
CLINICAL IMMUNOLOGY (2008)
Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation
Andrew E. Schade et al.
BLOOD (2008)
2-aminothiazole as a novel kinase inhibitor template.: Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor
Jagabandhu Das et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner
R Seggewiss et al.
BLOOD (2005)
A small molecule-kinase interaction map for clinical kinase inhibitors
MA Fabian et al.
NATURE BIOTECHNOLOGY (2005)
Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo
AB Dietz et al.
BLOOD (2004)
Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro
K Cwynarski et al.
LEUKEMIA (2004)
Active transport of imatinib into and out of cells: implications for drug resistance
J Thomas et al.
BLOOD (2004)
Regulation of the Src family kinase Lck by Hsp90 and ubiquitination
A Giannini et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Share Paper
